Mumbai | 5th September 2025 — In a significant leap forward for hair restoration science, QR678 Neo®, a next-generation, patented, Indian-developed biomimetic peptide formulation, has been clinically validated through a global study on hair transplant surgery,  published in the Journal of Cosmetic and Laser Therapy. The international trial, involving 112 men with advanced hair loss, was led by experts from India, the USA, and Malaysia, and confirms that QR678 Neo® delivers 43% better graft survival, fuller regrowth, and visibly improved hair quality than conventional transplant methods.

QR678 Neo® is a patented peptide therapy developed and clinically tested in India, and now also patented in the United States. With androgenetic alopecia impacting 85% of men by age 50 and 50% of women by age 60, the need for reliable and effective transplant outcomes has never been greater. Traditional storage mediums for extracted hair follicles, like cold saline, provide only temporary preservation and lack biological activity, often leaving grafts vulnerable to damage. Unlike such adjuncts — including saline or PRP — which offer only temporary support to hair follicles, QR678 Neo® plays an active biological role throughout the transplant process.

Administered in three stages — before, during, and after surgery — the therapy nourishes the scalp, protects grafts, and supports post-operative recovery. By mimicking the body’s natural growth factors with a proprietary blend of biomimetic peptides, it creates a regenerative environment that improves follicle survival, accelerates healing, and enhances the density and quality of regrown hair.

Even with state-of-the-art Follicular Unit Extraction (FUE) techniques, a key challenge remains poor graft survival rates, often resulting in patchy regrowth, inconsistent outcomes, and the need for repeat procedures. QR678 Neo® directly addresses this challenge by providing complete follicular support at all three stages of the transplant — rejuvenating the donor area, protecting extracted grafts, and enhancing transplanted hair regrowth.

This breakthrough addresses one of the long-standing challenges in hair restoration: poor graft survival. QR678 Neo® consistently delivered superior outcomes, including better hair growth, increased density, and higher patient satisfaction in hair transplant patients. The study was conducted by an international panel of experts, including Dr. Michael Gold (USA), Dr. Vinay Chouksey (India), Dr. Ungku Mohd Shahrin Mohd Zaman (Malaysia), and Dr. Mahesh Gosavi (India).

“What stood out in this study was not just the improvement in hair regrowth, but the consistency of results across patients and clinical settings. We’re seeing a clear shift — biologically active therapies like QR678 Neo® can support graft survival in ways that traditional methods simply haven’t. That’s a meaningful step forward for the field and for patients who’ve long faced unpredictable outcomes from hair restoration procedures.” — Dr. Michael H. Gold, Lead Investigator and Director, Gold Skin Care Center, USA

“Hair restoration surgery has long needed an intervention that could raise the baseline for results globally. With QR678 Neo®, we have moved beyond cosmetic expectations into the realm of clinically validated, biologically active therapy. What’s especially significant is that this innovation is now recognised internationally for its reproducibility, scalability, and real-world efficacy. We have seen exceptional results also in Malaysian patients.” — Dr. Ungku Shahrin, Consultant Dermatologist and Aesthetic Medicine Expert, Malaysia

“Patients are not just seeing greater regrowth post hair transplant surgery — they are experiencing faster recovery, more confidence, and fewer repeat surgeries. Fewer re-surgeries, faster healing – QR678 Neo® isn’t just better science, it’s better recovery. Hair transplant patients worldwide struggle with poor graft survival. A new Indian-led innovation may finally change that.” — Dr. Mahesh Gosavi, Dermatologist and co-author of the manuscript

“With the global hair restoration market valued at over $4 billion and rising, QR678 Neo® offers a timely solution that aligns with growing demand for minimally invasive regenerative therapies. As one of the few globally patented innovations, clinically validated by 14+ clinical trials globally, the QR678 Neo® reflects the transformative impact of hair regenerative therapy.” — Dr. Vinay Chouksey, top hair transplant surgeon and co-author of the manuscript.

QR678 Neo® is a patented, biologically active, non-blood-based regenerative formulation that enhances cellular viability, tissue healing, and vascularisation of graft sites. In clinical settings, it has consistently outperformed cold saline across every measure - follicle survival, hair density, regrowth rate, and patient satisfaction - while remaining minimally invasive and well-tolerated. Patented and clinically validated across geographies, QR678 Neo® underscores its global scalability and status as a breakthrough innovation.

With the global hair restoration market valued at over $4 billion, it arrives at a pivotal moment as a proven, scalable solution that also highlights India’s leadership in biotech-driven healthcare, delivering cross-border innovation with measurable patient benefit.

QR678® is a patented hair regenerative translational platform, from which breakthrough products like QR678 Neo® have emerged. With four global patents filed in the past year and five regenerative products currently in development, the QR678® platform is advancing towards a robust pipeline of hair signal-targeting therapies.

Backed by peer-reviewed studies and regulatory approval in India, QR678® is a non-invasive, clinically effective treatment that promotes follicle survival and scalp regeneration. It is patented in the US, India, EU, Australia, UK, and several other countries.

The current study on its impact in hair transplant surgery adds to 14 other peer-reviewed papers on QR678 Neo®’s effectiveness across a spectrum of hair loss conditions, reaffirming its position as one of the world’s most clinically validated hair regrowth innovations. Past studies have demonstrated benefits in alopecia areata, post-COVID hair loss, chemotherapy-induced alopecia, and PRP-resistant cases.

The QR678® regenerative dermatology research platform has also shown promise in treating scarring, chemo-induced alopecia, and other complex hair disorders. QR678 Neo® is already approved for cosmetic use in India and is widely used in clinics across the Middle East and South & East Asia, making it the leading hair regenerative solution in more than 10 countries.

With international partnerships underway and further global trials planned, QR678 Neo® is poised to redefine standards in regenerative hair science.

Media Contact & Resources
For interviews with Dr. Michael Gold, Dr. Ungku Shahrin, or other members of the international clinical team, and to access the full study PDF, high-resolution before/after visuals, or data summaries, please contact: